Literature DB >> 35958490

Constructing a novel prognostic signature of tumor driver genes for breast cancer.

Liqiang Zhou1, Yali Yi2, Chuan Liu3, Zhiqing Chen3.   

Abstract

OBJECTIVES: To systematically explore the function and prognostic ability of tumor-driver genes (TDGs) in breast carcinoma (BRCA).
METHODS: Functional enrichment analysis of BRCA differentially expressed TDGs was assesed. We used univariate Cox, lasso, and multivariate Cox regression to identify the independent prognostic TDGs of BRCA. Then we constructed a prognostic signature and verified its predictive performance. Gene set enrichment analysis of the signal pathway revealed the differences between the prognostic signature high- and low-risk groups. Finally, a nomogram related to the prognostic model was established and verified.
RESULTS: A total of 595 differentially expressed TDGs were identified, which are related to various molecular mechanisms of BRCA progression. We identified 8 independent prognostic TDGs for BRCA and validated their expression and prognosis with public data and clinical samples. The BRCA cohort was divided into training and validation cohorts, and prognostic signatures were constructed separately. The log-rank test showed that the survival rate of the high-risk group was significantly lower than that of the low-risk group in the prognostic signature (P<0.001); the AUC in the three cohorts were 0.805, 0.712, and 0.760, respectively; the nomogram also showed better predictive performance. Analyzing the difference between the two risk subtypes, the high-risk group is mainly enriched in angiogenesis, MTORC1, epithelial-mesenchymal transition and glycolysis, which means it is highly malignant.
CONCLUSIONS: The prognostic signature and nomogram was confirmed to accurately predict the prognosis of patients with BRCA and we validated the hub genes, suggesting their potential as future therapeutic targets. AJTR
Copyright © 2022.

Entities:  

Keywords:  Breast cancer; nomogram; prognostic signature; tumor drive gene

Year:  2022        PMID: 35958490      PMCID: PMC9360863     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   3.940


  48 in total

1.  Ezrin and BCAR1/p130Cas mediate breast cancer growth as 3-D spheroids.

Authors:  Sophya Konstantinovsky; Ben Davidson; Reuven Reich
Journal:  Clin Exp Metastasis       Date:  2012-04-04       Impact factor: 5.150

Review 2.  Molecular pathways: MERTK signaling in cancer.

Authors:  Christopher T Cummings; Deborah Deryckere; H Shelton Earp; Douglas K Graham
Journal:  Clin Cancer Res       Date:  2013-07-05       Impact factor: 12.531

3.  LEF-1 regulates proliferation and MMP-7 transcription in breast cancer cells.

Authors:  Vesna Bucan; Katharina Mandel; Catharina Bertram; Andrea Lazaridis; Kerstin Reimers; Tjoung-Won Park-Simon; Peter M Vogt; Ralf Hass
Journal:  Genes Cells       Date:  2012-06-12       Impact factor: 1.891

Review 4.  Advances in computational approaches for prioritizing driver mutations and significantly mutated genes in cancer genomes.

Authors:  Feixiong Cheng; Junfei Zhao; Zhongming Zhao
Journal:  Brief Bioinform       Date:  2015-08-24       Impact factor: 11.622

5.  The RNA binding protein FXR1 is a new driver in the 3q26-29 amplicon and predicts poor prognosis in human cancers.

Authors:  Jun Qian; Mohamed Hassanein; Megan D Hoeksema; Bradford K Harris; Yong Zou; Heidi Chen; Pengcheng Lu; Rosana Eisenberg; Jing Wang; Allan Espinosa; Xiangming Ji; Fredrick T Harris; S M Jamshedur Rahman; Pierre P Massion
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-02       Impact factor: 11.205

6.  TRIM11 facilitates chemoresistance in nasopharyngeal carcinoma by activating the β-catenin/ABCC9 axis via p62-selective autophagic degradation of Daple.

Authors:  Runa Zhang; Si-Wei Li; Lijuan Liu; Jun Yang; Guofu Huang; Yi Sang
Journal:  Oncogenesis       Date:  2020-05-07       Impact factor: 7.485

7.  Dual inhibition of ABCE1 and LCP1 by microRNA-96 results in an additive effect in breast cancer mouse model.

Authors:  Nir Pillar; Avital Luba Polsky; Noam Shomron
Journal:  Oncotarget       Date:  2019-03-12

8.  Statistical predictions with glmnet.

Authors:  Solveig Engebretsen; Jon Bohlin
Journal:  Clin Epigenetics       Date:  2019-08-23       Impact factor: 6.551

9.  FAM83H-AS1 is a noncoding oncogenic driver and therapeutic target of lung adenocarcinoma.

Authors:  Siwei Wang; Chencheng Han; Tongyan Liu; Zhifei Ma; Mantang Qiu; Jie Wang; Qingjun You; Xiufen Zheng; Weizhang Xu; Wenjia Xia; Youtao Xu; Jingwen Hu; Lin Xu; Rong Yin
Journal:  Clin Transl Med       Date:  2021-02

10.  CHD1L prevents lipopolysaccharide-induced hepatocellular carcinomar cell death by activating hnRNP A2/B1-nmMYLK axis.

Authors:  Guangliang Wang; Xiaofeng Zhang; Wei Cheng; Yanxuan Mo; Juan Chen; Zhiming Cao; Xiaogang Chen; Huiqin Cui; Shanshan Liu; Li Huang; Ming Liu; Lei Ma; Ning-Fang Ma
Journal:  Cell Death Dis       Date:  2021-09-29       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.